JAZZ · XBRL financial data

Jazz Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (JAZZ's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue from contracts with customers	1,012*	902	1,024	1,055	1,088*	898	1,046	1,126	1,198*	1,069	1,208	1,243
Selling, general and administrative	396*	352	339	326	369*	514	358	531	406*	353	389	408
Operating income (loss)	122*	66	199	260	191*	(56)	(686)	58	255*	337	248	(413)
Interest income	21*	23	25	26	32*	28	19	19	21*	23	25	23
Interest expense	year only	—	—	—	—	—	—	—	—	—	—	—
Income tax expense (benefit)	(33)*	12	(31)	(15)	(58)*	(18)	(17)	(242)	5*	6	18	25
Net income (loss)	94*	(15)	169	215	191*	(93)	(718)	251	203*	293	193	(483)
Earnings per share, basic USD per share	1.50*	(0.23)	2.68	3.50	3.16*	(1.52)	(11.74)	4.14	3.33*	4.73	3.05	(7.48)
Earnings per share, diluted USD per share	1.35*	(0.23)	2.49	3.42	2.78*	(1.52)	(11.74)	4.08	3.38*	4.43	2.78	(7.48)
Weighted average shares, basic millions of shares	63*	63	63	61	61*	61	61	61	61*	62	63	65
Weighted average shares, diluted millions of shares	70*	63	70	63	69*	61	61	62	60*	66	69	65

Fiscal quarters (JAZZ's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	1,506	1,443	1,356	2,218	2,413	1,862	1,190	1,326	1,392	1,844	1,620	2,036
Accounts receivable	706	707	698	724	717	653	714	764	831	836	881	874
Inventory	597	577	543	539	480	493	505	483	417	438	443	454
Total current assets	3,435	3,540	3,682	4,390	4,629	4,128	3,350	3,756	4,166	4,583	3,968	4,613
Right-of-use asset	65	62	73	77	54	49	63	61	59	56	52	67
Goodwill	1,753	1,739	1,736	1,805	1,716	1,760	1,844	1,827	1,829	1,805	1,800	1,803
Total assets	11,393	11,327	11,362	12,256	12,012	11,535	10,944	11,356	11,659	11,860	11,081	11,998
Accounts payable	103	81	97	85	78	96	89	152	122	100	129	380
Accrued liabilities	794	827	801	859	911	1,064	875	1,002	1,034	1,022	1,030	1,076
Current portion of long-term debt	605	605	606	31	31	31	1,028	1,029	1,030	1,031	1,016	1,017
Total current liabilities	1,537	1,562	1,556	1,030	1,039	1,223	2,071	2,274	2,243	2,247	2,231	2,533
Long-term debt	5,108	5,105	5,101	6,081	6,078	5,336	4,336	4,332	4,328	4,324	3,335	4,552
Lease liability, non-current	59	56	68	71	39	39	55	53	51	47	44	61
Retained earnings	879	864	871	936	1,127	1,035	191	443	646	939	1,132	424
Total stockholders' equity	3,737	3,696	3,763	4,171	4,094	4,175	3,706	3,959	4,319	4,532	4,802	4,192
Total liabilities and equity	11,393	11,327	11,362	12,256	12,012	11,535	10,944	11,356	11,659	11,860	11,081	11,998
Common shares outstanding (cover page) millions of shares	62	63	62	60	61	62	61	61	62	63	65	64

Fiscal quarters (JAZZ's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	94*	(15)	169	215	191*	(93)	(718)	251	203*	293	193	(483)
Stock-based compensation	53*	61	57*	60*	70*	68	65*	88*	71*	75	73*	77*
Depreciation and amortization	year only	—	—	—	year only	—	—	—	year only	—	—	—
Net cash from operating activities	167*	267	331*	399*	399*	430	89*	475*	363*	408	416*	506*
Purchases of property and equipment	10*	7	7*	11*	13*	14	13*	15*	17*	20	18*	16*
Net cash from investing activities	102*	(272)	(257)*	214*	(193)*	(169)	(641)*	(328)*	(372)*	123	355*	(1,084)*
Share repurchases	100*	—	—	150*	0*	—	—	0*	0*	—	—	225*
Net cash from financing activities	(100)*	(57)	(161)*	246*	(8)*	(813)	(125)*	(11)*	75*	(79)	(995)*	994*
Net change in cash	171*	(63)	(88)*	862*	195*	(551)	(672)*	136*	66*	452	(225)*	417*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Jazz Pharmaceuticals	2,036	1,243	506*	64.2M	—	Q3 FY26 10-QSep 30, 2026
Corcept Therapeutics	99	340	143*	109.4M	—	Q3 FY26 10-QSep 30, 2026
Repligen	727	209	43*	63.9M	—	Q3 FY26 10-QSep 30, 2026
Biomarin Pharmaceutical	736	1,025	188*	193.7M	—	Q3 FY26 10-QSep 30, 2026
Revolution Medicines	815	not reported	(387)*	214.3M	10.2 quarters	Q2 FY26 10-QJun 30, 2026
Madrigal Pharmaceuticals	515	431	121*	23.2M	—	Q3 FY26 10-QSep 30, 2026
Ionis Pharmaceuticals	350	268	566*	166.2M	—	Q2 FY26 10-QJun 30, 2026
Alkermes	631	480	93*	168.0M	—	Q3 FY26 10-QSep 30, 2026
Halozyme Therapeutics	163	481	241*	113.5M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.